Fresh preclinical ORY-2001 data, ORY-1001 next
Oryzon’s Q316 update revealed good progress on R&D and it reiterated that the preliminary Phase I/IIa data for ORY-1001 is expected to be presented at the American Society of Hematology (ASH) annual meeting on 3 to 6 December 2016. The focus will be on Part 2 of the study, which should include preliminary efficacy information. Oryzon has also made progress with earlier R&D projects, with fresh preclinical ORY-2001 data in September demonstrating potential in a new multiple sclerosis indication, and revealed, in July, a third product, ORY-3001, targeting undisclosed non-oncological indications. Our Oryzon valuation is virtually unchanged at €156m or €5.5/share.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.